SyMRI 3D reportedly combines precise estimates of regional brain volume with improved resolution bolstering accuracy with lesion analysis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SyMRI 3D, a modality that may offer enhanced resolution and accuracy for brain magnetic resonance imaging (MRI) scans.
Combining quantitative MRI technology with isotropic resolution, SyMRI 3D provides improved accuracy in brain lesion analysis and facilitates brain structure and function assessments through precise brain region volume estimates, according to SyntheticMR U.S., the developer of the SyMRI 3D modality.
The newly FDA-cleared SyMRI 3D reportedly provides improved resolution that enhances accuracy of brain lesion analysis and better precision of brain region volume estimates, according to SyntheticMR U.S., the developer of the modality. (Image courtesy of SyntheticMR U.S.)
“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," said Jared Dixon, the president of SyntheticMR U.S.
SyMRI 3D will also be available to Philips customers as per a recently expanded partnership agreement between the two companies that was announced in November 2023.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.